Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics

This publication has 21 references indexed in Scilit:

• The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity
  Canadian Journal of Physiology and Pharmacology, 1990
• The effect of three dose levels of ICS 205–930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1989
• Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
  Journal of Clinical Oncology, 1989
• GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
  Journal of Clinical Oncology, 1989
• GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting
  Cancer Chemotherapy and Pharmacology, 1989
• Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy
  European Journal of Cancer and Clinical Oncology, 1989
• Phase II Trials of the Serotonin Antagonist GR38032F for the Control of Vomiting Caused by Cisplatin
  JNCI Journal of the National Cancer Institute, 1989
• The efficacy of GR38032F, an Antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1988
• Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
  Journal of Clinical Oncology, 1988
• FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS
  The Lancet, 1987